Enterprise 2支架在重度颅内动脉动脉粥样硬化性狭窄患者中的临床应用  

The preliminary study of Enterprise 2 stent in the treatment of severe intracranial atherosclerotic stenosis

作　　者：范承哲[1] 王力锋[1] 马玉栋 郭旭[1] 于蕾[1] 何晓芬[1] 张楠[1] FAN Chengzhe;WANG Lifeng;MA Yudong;GUO Xu;YU Lei;HE Xiaofen;ZHANG Nan(Department of Intervention Neurosurgery,Beijing Anzhen Hospital,Capital Medical University,Beijing Institute of Heart,Lung and Blood Vessel Diseases,Beijing 100029,China)

机构地区：[1]首都医科大学附属北京安贞医院-北京市心肺血管疾病研究所神经介入科,100029

出　　处：《心肺血管病杂志》2022年第12期1253-1257,共5页Journal of Cardiovascular and Pulmonary Diseases

摘　　要：目的:评价Enterprise 2支架在重度动脉粥样硬化性颅内动脉狭窄患者治疗中的安全和有效性。方法:回顾性分析2019年4月至2021年11月,于首都医科大学附属北京安贞医院神经介入科采用Enterprise 2支架进行治疗的21例重度动脉粥样硬化性颅内动脉狭窄患者资料(规范药物治疗下仍有缺血性卒中发作),所有患者术前行数字减影全脑血管造影以明确诊断,术后30d、6个月随访,主要终点事件定义为术后30d内发生的短暂性脑缺血发作(TIA)、出血性或缺血性脑卒中、任何原因引起的死亡。结果:21例患者支架置入成功率100%,支架置入后责任血管狭窄率由(88.66.7)%降为(21.810.1)%,差异有统计学意义(t=35.12,P<0.001);主要终点事件发生率为4.8%,术后6个月随访支架内再狭窄发生率为5.0%。术后6个月内TIA发生率5.0%,无缺血性脑卒中及死亡病例。结论:Enterprise 2支架在规范药物治疗效果不佳、血管病变复杂的重度动脉粥样硬化性颅内动脉狭窄患者的治疗中安全有效,但仍需长期随访、多中心随机对照研究加以验证。Objective:To evaluate the safety and clinical efficacy of Enterprise 2 stent in the treatment of severe intracranial atherosclerotic stenosis(ICAS).Methods:21 patients with severe ICAS underwent Enterprise 2 stent angioplasty in our department from April 2019 to November 2021 were included in present study.All patients were diagnosed as severe ICAS by digital subtraction angiography(DSA)before endovascular intervention.Follow-up information was reviewed by study neurologists at 30 days and 6 months after the procedure via face to face interview.The primary endpoints were transient ischemic attack(TIA),ischemic or hemorrhagic stroke and death caused by any reason within 30 days.Results:The overall technical success rate was 100%.The average stenosis rate was reduced from(88.66.7)%to(21.810.1)%,t=35.12,P<0.001.The primary end point event was 4.8%.During the follow-up period,one patient developed to TIA and no death or ischemic stroke was observed.One patient developed to in-stent restenosis at six months after stenting.Conclusions:Enterprise 2 stent is safe and effective for the treatment of patients with severe ICAS.However,it needs to be further validated via longer follow-up and multicenter randomized controlled studies.

关 键 词：颅内动脉狭窄 动脉粥样硬化 血管内治疗 Enterprise 2支架 

分 类 号：R54[医药卫生—心血管疾病]